je.st
news
Tag: biologics
South Dakota biologics center to improve animal, human health
2017-07-06 11:00:00| National Hog Farmer
New center brings together researchers from two universities South Dakota State University and the University of South Dakota and four departments, veterinary and biomedical sciences, health and nutritional sciences and biology and microbiology at SDSU and basic biomedical sciences at the USD Sanford Medical School.
Tags: health
center
south
improve
Green Biologics Achieves REACH Certification
2017-06-29 16:39:00| Coatings World Breaking News
Tags: green
reach
certification
achieves
Merck Receives FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
2017-01-10 22:06:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Submission Based on Data from KEYNOTE-021 Trial, Cohort G, Which Enrolled Patients Regardless of PD-L1 Expression KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: application
license
cell
treatment
FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Mercks KEYTRUDA (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma
2016-12-01 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or for patients who have relapsed after three or more prior lines of therapy. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: review
application
license
classical
FDA Grants Priority Review to Mercks Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer
2016-11-28 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of previously treated patients with advanced microsatellite instability-high (MSI-H) cancer. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: review
application
license
approval
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »